A 3-month course of romosozumab followed by denosumab provides similar BMD gains to those seen with 12 months of romosozumab in women with postmenopausal osteoporosis.
PSMA-617 to androgen deprivation therapy (ADT) with androgen receptor pathway inhibitor (ARPI) bettered disease control in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according ...
Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...
On January 19, 2026, Hikma announced the U.S. launch of ENOBY (denosumab-qbde) and XTRENBO (denosumab-qbde)—denosumab biosimilars referencing Amgen’s PROLIA and XGEVA, respectively. As recited in the ...
Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen ...
Treatment strategies after denosumab discontinuation in non-metastatic breast cancer treated with AI
Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen ...
Korean regulators have approved two denosumab biosimilars from HK inno.N, setting up a sharper fight in a market where Amgen’s Prolia (denosumab) and Xgeva (denosumab) have generated more than 180 ...
aDepartment of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria bDepartment of Oral and Maxillofacial Surgery, Medical University Salzburg, Salzburg, Austria gInstitute ...
1Dana-Farber-Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts. *Corresponding Author: Katherine A. Janeway, Department of Pediatric Oncology, Dana-Farber-Boston Children’s ...
Biosimilar denosumab offers significant cost savings and improved access to treatment, alleviating financial burdens in oncology care while enhancing patient outcomes. The rising cost of oncology care ...
Credit: Celltrion. The FDA originally approved Stoboclo and Osenvelt as biosimilars in March 2025. The interchangeability designation allows Stoboclo and Osenvelt to be substituted at the pharmacy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results